We spoke with Ryan & Jesse from Vine Ventures about how court cases may pave the way for psychedelic rights & more.
Similar Posts
MindMed’s Q2 Earnings Call: What does the future hold for MNMD/ MMED?
Check out atai Life Sciences’ earnings call: https://www.youtube.com/watch?v=lkE3EmU0o_w
What’s up psychedelic stocks investors?!? Today marked MindMed’s (MNMD /MMED) Second Quarter 2021 conference call. In the conference call, MindMed gave updates on their varying projects, such as treating anxiety with LSD, addiction with 18MC, and pain with LSD. They also give insights into their digital medicines division and gave an update on their hiring spree.
This Kevin O’Leary-backed psychedelic therapies company is fighting for the title of the most advanced psychedelic stock. With 17+ different projects under their belt, MindMed is one of the most exciting companies to keep an eye on in the industry.
This conference call can help investors answer the questions: is MNMD stock a good investment? Will MMED go up? Are psychedelic stocks / shroom stocks good investments? Can psychedelics heal depression? Can psychedelics be used for mental health?
Enjoy the episode!
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Check out our website: thepsychedelicinvestor.com
Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
#MindMed #MNMD #PsychedelicStocks
Interview With Dr. Gorman
In this episode of the Psychedelic Spotlight podcast, we speak with Dr. Ingmar Gorman who is the Co-Founder and Lead Trainer at Fluence, and a Principal Investigator for the Multidisciplinary Association for Psychedelic Studies (“MAPS”).ya Health’s Co-Founder and CEO, David Champion, discusses the importance of data and analytics in the growing psychedelic community.
SPOTLIGHT IN FOCUS – The Rise of Psychedelic Therapy
Dr. Zinia Thomas at Radiance Wellness, St. Louis MO –…
Ketamine Therapy for High Performance Athletes with Dr. Sam Zand and Derek Du Chesne
In this episode, we discuss how ketamine therapy can help high-performance professional athletes and corporate executives.
Field Trip And Wesana Make Major Moves | FTRP, WESA
Get your 20%-off tickets to the Catalyst Psychedelics Summit in Kingston Ontario, May 20th-23rd:
www.eventbrite.ca/e/153409882087/?discount=SPOTLIGHT20
Join our Newsletter (scroll to the bottom of the page and sign up):
https://psychedelicspotlight.com/
Wesana Health May Sell Clinics to Focus Solely on Drug Development: An Analysis
https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Why Field Trip Health Is Dividing in Two — and What This Means for Investors
https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
In today’s episode of the Psychedelic Investor, I discuss two major stories. First, is the news that Field Trip Health (Nasdaq: FTRP, TSX: FTRP) will be splitting into two separate companies.
Next, Wesana Health (CSE: WESA, OTCQB: WSNAF) announced that they are considering selling all of their non-drug development assets, including their Psychedelic Therapy clinics.
Follow us on Twitter:
James: @Psy_Invest
Maria: @psy_holy
The Psychedelic Investor: @PSYCBiz
Psychedelic Spotlight: @PsycSpotlight
Follow us on Instagram:
@psycbiz
@psycspotlight
To read more about the Field Trip situation: https://psychedelicspotlight.com/field-trip-health-dividing-two-companies-reunion-neuroscience/
To read more about the Wesana situation: https://psychedelicspotlight.com/wesana-health-may-sell-clinics-to-focus-solely-on-drug-development-an-analysis/
Field Trip Press Release: https://www.globenewswire.com/news-
release/2022/04/28/2432105/0/en/Field-Trip-Health-Ltd-Announces-Intention-to-Separate-the-Field-Trip-Discovery-and-Field-Trip-Health-Divisions-Into-Two-Independent-Public-Companies.html
Wesana Press Release: https://ir.wesanahealth.com/news-events/press-releases/detail/41/wesana-announces-singular-focus-on-drug-development
Field Trip Health:
In a surprise move, Field Trip Health Ltd. announced on Thursday that they will be separating their company into two independent publicly traded entities.
Assuming the ratification of shareholders and regulatory approval, come July 2022, Field Trip Health will be no more. From its ashes will rise Reunion Neuroscience Inc, and Field Trip Health and Wellness Ltd.
Reunion will be the successor to Field Trip’s Discovery division, which was the part of the company which worked on next-generation psychedelics. This includes FT-104, a psilocybin-like compound that is a prodrug to 4-HO-DiPT, and the company’s FT-200 series of psychedelics, which they call third-generation.
Wesana:
On Thursday, Wesana Health made a major announcement. Following a planned strategic review of their assets, Wesana is considering options “including, but not limited to, a sale of all the assets under the care delivery division,” including all of their psychedelic therapy clinics.
The core reasoning, according to the press release, is that Wesana wants to focus its efforts entirely on its drug development division.
Prior to this announcement, Wesana was operating under a philosophy centered on “developing the novel therapies of tomorrow and delivering new care paradigms today.” If this strategic review does result in the sale of their clinics and other today-focused ventures, then Wesana will be decidedly much more focused on tomorrow.
@psycspotlight #wesana #psychedelicstocks #thepsychedelicinvestor
What If Your Child Asked to Watch You Do Drugs With Matt Zemon
In this episode, David Flores speaks with Matt Zemon, the co-founder of Happy and author of Psychedelic for Everyone. They open up about deeply personal stories about their childhood, with Matt sharing a beautiful story about connecting with his son Cole.